Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic Disease

Blood Clots: When Should You Stop Anticoagulation?Подробнее

Cancer-Associated Thrombosis and Antiphospholipid Syndrome: An Update for CliniciansПодробнее

Review of Key Principles of ThrombosisПодробнее

Edoxaban for the treatment of cancer-associated venous thromboembolismПодробнее

The use of anticoagulants in cancer-associated venous thromboembolismПодробнее

The Reversal of Betrixaban - Induced AnticoagulationПодробнее

Edoxaban for Cancer-Associated Venous ThromboembolismПодробнее

A New Look at Cancer-Associated Venous Thromboembolism: Emerging Evidence's Influence on GuidelinesПодробнее

Encephalitis After COVID-19 Vaccine Administration: PerspectivesПодробнее

Alok Khorana: Rivaroxaban Prevents Cancer-Associated VTEПодробнее

Improving Quality of VTE CareПодробнее

Rivaroxaban reduces burden of cancer-associated venous thromboembolic diseaseПодробнее

Grand Rounds: Cancer Thrombosis with Dr. RojanПодробнее

Anticoagulation Strategies for Pulmonary Embolism (KEYNOTE)Подробнее

Medical Therapy for Venous Thromboembolism | Gregory Piazza, MD, MSПодробнее

How is cancer-related venous thromboembolism treated in real world practice?Подробнее

Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic DiseaseПодробнее

Quality assessment looking at rivaroxaban for cancer-related thrombosisПодробнее

Rivaroxaban in Cancer-Associated VTE: Results from CALLISTOПодробнее